Immunome Inc. Share-based Payment Arrangement, Expense in USD from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Immunome Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2019 to Q3 2025.
  • Immunome Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $6.75M, a 37.9% increase year-over-year.
  • Immunome Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $23.3M, a 76.8% increase year-over-year.
  • Immunome Inc. annual Share-based Payment Arrangement, Expense for 2024 was $15.7M, a 153% increase from 2023.
  • Immunome Inc. annual Share-based Payment Arrangement, Expense for 2023 was $6.22M, a 16.7% increase from 2022.
  • Immunome Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5.33M, a 54.6% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Immunome Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $23.3M $6.75M +$1.86M +37.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $21.4M $5.35M +$2.12M +65.7% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 $19.3M $5.7M +$3.54M +164% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q4 2024 $15.7M $5.47M +$2.59M +89.7% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-19
Q3 2024 $13.2M $4.89M +$3.81M +352% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $9.35M $3.23M +$2.19M +212% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 $7.16M $2.16M +$935K +76.4% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q4 2023 $6.22M $2.88M +$1.53M +113% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-19
Q3 2023 $4.7M $1.08M -$257K -19.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $4.95M $1.03M -$294K -22.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $5.25M $1.22M -$86K -6.57% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $5.33M $1.36M +$136K +11.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $5.2M $1.34M +$185K +16% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $5.01M $1.33M +$578K +77.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $4.43M $1.31M +$985K +303% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 $3.45M $1.22M +$1.58M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 $1.87M $1.16M +$355K +44.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1.51M $749K +$710K +1821% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $800K $325K +$179K +123% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $621K -$364K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 $800K +$799K Sep 1, 2020 Sep 30, 2020 10-Q 2020-11-16
Q3 2020 $117K +$116K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $39K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $146K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q3 2019 $1K* Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16

Immunome Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $15.7M +$9.53M +153% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-19
2023 $6.22M +$891K +16.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-19
2022 $5.33M +$1.88M +54.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $3.45M +$2.83M +455% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 $621K +$607K +4336% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
2019 $14K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.